Required baseline labs include estradiol, progesterone, total testosterone, free testosterone, SHBG, FSH, LH, thyroid panel (TSH, free T3, free T4), complete metabolic panel (CMP), CBC with differential, and lipid panel. Labs are ordered through Quest Diagnostics or Rupa Health and must be completed before your initial consultation. This panel gives your provider a full hormonal picture — not just a single estradiol level — so your protocol is built on your actual numbers.

For appropriate candidates who are properly monitored, bioidentical HRT has a well-supported safety profile. Bioidentical hormones are molecularly identical to the hormones your body produces naturally, which is a structural distinction — not a marketing claim. Most of the safety concerns women have heard — blood clots, breast cancer risk, cardiovascular effects — are rooted in the 2002 Women's Health Initiative, which studied synthetic conjugated equine estrogens and medroxyprogesterone acetate. Those are not what we prescribe. Bioidentical micronized progesterone and transdermal estradiol have meaningfully different risk profiles. HRT is not appropriate for all women: hormone-sensitive cancers, active cardiovascular disease, uncontrolled clotting disorders, and unexplained vaginal bleeding are contraindications assessed at intake. Individual health history determines candidacy — that's what the lab panel and consultation are for.

The clot risk associated with HRT is route-dependent, not inherent to hormone therapy itself. Oral estrogen is processed through the liver and can elevate clotting factors — that's where the elevated risk data comes from. Transdermal estradiol (cream or patch) bypasses hepatic metabolism entirely, and clinical evidence consistently shows it carries no meaningful increase in clot risk for women without pre-existing clotting disorders. Women with a history of deep vein thrombosis, pulmonary embolism, or thrombophilia are evaluated individually — in many cases transdermal delivery is still an option, but that determination is made by your provider after a full history review.

Cyclic HRT provides estrogen daily with progesterone added for 10–14 days per month, producing a predictable monthly bleed that mimics a natural cycle. It's typically used in women who are recently perimenopausal and still have some hormonal cycling. Continuous HRT provides both estrogen and progesterone daily without interruption, stabilizing hormone levels and eliminating monthly bleeding over time — preferred for women who are fully postmenopausal or who prefer no cycle. The right approach depends on where you are in the menopause transition and is determined at your consultation based on labs and symptom history.

Yes — for most women, testosterone is an essential component of a complete HRT protocol, not an optional add-on. Testosterone in women supports libido, energy, mood, cognitive clarity, lean muscle mass, bone density, and metabolic function. Levels decline gradually through the 30s and 40s and drop significantly at menopause. Women prescribed HRT without testosterone often continue to experience fatigue, brain fog, and low motivation because the deficiency driving those symptoms was never addressed. At Steel City, SHBG and free testosterone are measured at baseline to determine whether supplementation is indicated and at what dose. Female testosterone dosing is significantly lower than male TRT — typically 10–20% of male doses — and is calibrated to optimize without virilizing.

Dose control. With transdermal cream, the dose can be adjusted at any follow-up based on labs and symptom response — if your estradiol is running too high or too low, the fix is a quick protocol change. With pellets, once inserted the dose is fixed for 3–6 months. If the dose is wrong — too high causing side effects, too low providing inadequate relief — there's no correction available until the pellet is exhausted. Pellets also carry procedural risks (infection, extrusion) and can produce supraphysiologic hormone spikes immediately post-insertion. For most women, the flexibility and precision of transdermal delivery produces better long-term outcomes than a set-and-forget approach.

Yes, and for most women we still recommend it. The conventional reasoning is that progesterone is only necessary to protect the uterine lining from unopposed estrogen — which is accurate as far as it goes. But progesterone has significant systemic effects independent of uterine protection: it supports sleep quality, reduces anxiety, has neuroprotective properties, and helps balance the stimulating effects of estrogen in breast tissue. Bioidentical oral micronized progesterone in particular has a direct calming effect on GABA receptors, which is why many women report better sleep within the first few weeks. Whether to include progesterone post-hysterectomy is decided based on individual history and preference — it's not automatic, but it's often beneficial.

Different hormones, different doses, different purpose. Hormonal birth control uses synthetic progestins and, in combined methods, synthetic ethinyl estradiol — these are structurally distinct from the body's natural hormones, designed to suppress ovulation and the natural hormone cycle entirely. HRT uses bioidentical hormones at physiologic replacement doses — not suppressive doses — designed to restore levels that have declined. The downstream effects are different as well: synthetic oral contraceptives can lower SHBG (binding more free testosterone), suppress libido, and alter mood in ways that are well-documented. Bioidentical HRT at appropriate doses works with the body's hormonal physiology rather than overriding it.

Steel City provides telehealth HRT services to women physically located in Colorado, Arizona, Idaho, Maine, Montana, New Hampshire, New Mexico, Washington, and Wyoming. Patients must be located in a state where Steel City holds active licensure at the time of their telehealth visit. Lab work is ordered through Quest Diagnostics or Rupa Health, and compounded medications are shipped directly to your home.

Low estrogen in women is associated with hot flashes, night sweats, vaginal dryness, disrupted sleep, brain fog, mood changes including irritability and anxiety, reduced bone density, dry skin, and decreased libido. These symptoms can occur during perimenopause, after surgical menopause, or at any age when estrogen production declines. A comprehensive lab panel including estradiol, FSH, and LH is the only reliable way to confirm deficiency and guide treatment.

Most women notice initial changes within 3–6 weeks of reaching therapeutic hormone levels. Sleep and mood typically improve first, followed by energy and cognitive clarity. Libido and body composition changes take longer — usually 8–12 weeks for meaningful improvement, with continued progress over 6–12 months. Full optimization often requires one or two protocol adjustments based on follow-up labs at weeks 6 and 12.